Trial Profile
A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Assessing the Therapeutic Efficacy of Botulinum Toxin In Treating Scleroderma-Associated Raynaud's Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Raynaud's disease; Scleroderma
- Focus Therapeutic Use
- 20 Apr 2017 Primary endpoint has been met. (Change in Digital Blood Flow From Pre- to Post-injection.) as per results published in the Arthritis and Rheumatology
- 20 Apr 2017 Results published in the Arthritis and Rheumatology
- 28 Oct 2016 Status changed from active, no longer recruiting to completed.